SavedAdd your journal

Journals / Experimental Biomedical Research / 2022 / Cilt: 5 - Sayı: 2

Development and validation of UV/VIS spectroscopy method for determination of atezolizumab in pharmaceutical products

Meliha EKİNCİ
Hasan AKBABA
Ralph SANTOS-OLİVEİRA
Derya ILEM-OZDEMİR
Pages
175–182
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: The data corroborates the reliability as applicability of the developed UV/Vis spectroscopy method for quantitatively determining the amount of atezolizumab in pharmaceutical products.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The aim of this study was to develop and validate a simple, fast, and reliable UV visible methodology for the determination of atezolizumab in pharmaceutical products.
📊
Key Findings & Data:Results: According to the experimental data, the developed method was linear in a range varying from 0.10 to 1.50 mg.mL-1 determined by 6 individuals calibrations points.
💡
Conclusion & Impact:Conclusion: The data corroborates the reliability as applicability of the developed UV/Vis spectroscopy method for quantitatively determining the amount of atezolizumab in pharmaceutical products.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Aim: The aim of this study was to develop and validate a simple, fast, and reliable UV visible methodology for the determination of atezolizumab in pharmaceutical products. Methods: The maximum wavelength of atezolizumab was determined using a UV/Vis spectrum and the calibration curve has been established. Validation studies were carried out to determine the reliability of the spectrophotometer method used in quantification of pharmaceutical products. Results: According to the experimental data, the developed method was linear in a range varying from 0.10 to 1.50 mg.mL-1 determined by 6 individuals calibrations points. The r2 value was 0.9995 indicating a 99.95% correlation in linearity and precision. The robustness showed good and similar values and the limit of detection and limit of quantification were 0.005 mg.mL-1 and 0.018 mg.mL-1, respectively. Conclusion: The data corroborates the reliability as applicability of the developed UV/Vis spectroscopy method for quantitatively determining the amount of atezolizumab in pharmaceutical products.

🔖

Cite This Article

EKİNCİ, M., AKBABA, H., SANTOS-OLİVEİRA, R., ILEM-OZDEMİR, D. (2022). Development and validation of UV/VIS spectroscopy method for determination of atezolizumab in pharmaceutical products. Experimental Biomedical Research, Cilt: 5 - Sayı: 2, 175–182. https://ajindex.com/articles/418480

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Sau S, Petrovici A, Alsaab HO, et al. PDL-1 antibody drug conjugate for selective Chemo-guided immune modulation of cancer. Cancers (Basel). 2019
  2. 11(2): 232. [2]Deng R, Bumbaca D, Pastuskovas CV, et al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. MAbs. 2016
  3. 8(3): 593–603. [3]Atezolizumab. In: FDA label. [cited 2020 May 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_ docs/label/2019/761034s014lbl.pdf [4]Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012
  4. Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: Present and promise. Crit Rev Oncol Hematol. 2005
  5. 54(1): 11–29. [6]Martinelli E, De Palma R, Orditura M, et al. Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol. 2009
  6. 158(1): 1–9. [7]Chari RVJ. Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc Chem Res. 2008
  7. 41(1): 98–107. [8]Ordás I, Mould DR, Feagan BG et al. Anti- TNF monoclonal antibodies in inflammatory bowel disease: Pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012
  8. 91(4): 635–46. [9]Liu JKH. The history of monoclonal antibody development - Progress, remaining challenges and future innovations. Ann Med Surg. 2014
  9. 3(4): 113–16. [10] Heremans H, Dillen C, Groenen M, et al. Chronic relapsing experimental autoimmune encephalomyelitis (CREAE) in mice: Enhancement by monoclonal antibodies against interferon-γ. Eur J Immunol. 1996
  10. 26(109: 2393–98. [11] Mauri C, Mars LT, Londei M. Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process. Nat Med. 2000
  11. 6(6): 673–79. [12] Cerqueira-Coutinho C, Missailidis S, Alessandra-Perini J, et al. Comparison of biodistribution profile of monoclonal antibodies nanoparticles and aptamers in rats with breast cancer. Artif Cells Nanomedicine Biotechnol. 2017
  12. 45(3): 598–601. [13] Allan PM, Garson JA, Harper EI, et al. Biological characterization and clinical applications of a monoclonal antibody recognizing an antigen restricted to neuroectodermal tissues. Int J Cancer. 1983
  13. 31(5): 591–98. [14] Ligiero T, Souza Albernaz M, de Carvalho S, et al. Monoclonal antibodies: Application in radiopharmacy. Curr Radiopharm. 2014
  14. 6(4): 231–48. [15] Helal-Neto E, Cabezas SS, Sancenón F, et al. Indirect calculation of monoclonal anti